AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 16 - (NewsRx.com & NewsRx.net) -- Intracranially administered anti-A-beta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.
According to recent research published in the Journal of Neuroscience, "Active immunization against the beta-amyloid peptide (A-beta) with vaccines or passive immunization with systemic monoclonal anti-A-beta antibodies reduces amyloid deposition and improves cognition in APP transgenic mice. In this report, intracranial administration of anti-A-beta antibodies into frontal cortex and hippocampus of Tg2576 transgenic APP mice is described."
"The antibody injection resulted initially in a broad distribution of staining for the antibody, which diminished over 7 days," reported Donna M. Wilcock and collaborators at the University of South Florida in the United States. "Although no loss of immunostaining for deposited A-beta was apparent at 4 hours, a dramatic reduction in the A-beta load was discernible at 24 hours and was maintained at three and seven days. A reduction in the thioflavine-S-positive compact plaque load was delayed until three days, at which time microglial activation also became apparent."
"At one week after the injection, microglial activation returned to control levels, whereas A-beta and thioflavine-S staining remained reduced," said Wilcock and her ...
Source: HighBeam Research, Anti-A-beta antibodies reduce beta-amyloid deposition.